Evidence map›Paper›PMID 31285513›Full record

ArticleScientific reports2019

Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing.

Víctor Lorca, Daniel Rueda, Lorena Martín-Morales, María Jesús Fernández-Aceñero, Judith Grolleman, Carmen Poves, Patricia Llovet, Sandra Tapial, Vanesa García-Barberán, Julián Sanz and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. How many is too many? Polyposis syndromes and what to do next.Current opinion in gastroenterology · 2022
    Review
  9. Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Víctor LorcaLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain.
Daniel RuedaLaboratorio de Cáncer Hereditario, Servicio de Bioquímica, i + 12, Hospital 12 de Octubre, Madrid, Spain.
Lorena Martín-MoralesLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain.
María Jesús Fernández-AceñeroServicio de Anatomía Patológica, Hospital Clínico San Carlos, Madrid, Spain.
Judith GrollemanDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Carmen PovesServicio de Aparato Digestivo, Hospital Clínico San Carlos, Madrid, Spain.
Patricia LlovetLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain.ORCID http://orcid.org/0000-0003-0190-2105
Sandra TapialLaboratorio de Cáncer Hereditario, Servicio de Bioquímica, i + 12, Hospital 12 de Octubre, Madrid, Spain.
Vanesa García-BarberánLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain.
Julián SanzServicio de Anatomía Patológica, Hospital Clínico San Carlos, Madrid, Spain.
Pedro Pérez-SeguraServicio de Oncología Médica, Hospital Clínico San Carlos, CIBERONC, Madrid, Spain.ORCID http://orcid.org/0000-0001-5049-7199
Richarda M de VoerDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Eduardo Díaz-RubioServicio de Oncología Médica, Hospital Clínico San Carlos, CIBERONC, Madrid, Spain.
Miguel de la HoyaLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain.
Trinidad CaldésLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain.
Pilar GarreLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain. pilar_garre@hotmail.com.ORCID http://orcid.org/0000-0001-8285-4138
Hospital Clínico San Carlos · ESHospital Universitario 12 De Octubre · ESRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Attenuated adenomatous polyposis (AAP) is a heterogeneous syndrome in terms of clinical manifestations, heritability and etiology of the disease. Genetic heterogeneity and low penetrance alleles are probably the best explanation for this variability. Certainly, it is known that APC and MUTYH are high penetrance predisposition genes for adenomatous polyposis, but they only account for 5-10% of AAP. Other new predisposition genes, such as POLE, POLD1, NTHL1, AXIN2 or MSH3, have been recently described and have been associated with AAP, but their relative contribution is still not well defined. In order to evaluate the genetic predisposition to AAP in a hospital based population, germline DNAs from 158 AAP subjects were screened for genetic variants in the coding regions and intron-exon boundaries of seven associated genes through a next-generation sequencing (NGS) custom gene panel. Splicing, segregation studies, somatic mutational screening and RNA quantitative expression assays were conducted for selected variants. In four of the probands the adenoma susceptibility could be explained by actionable mutations in APC or MUTYH, and one other patient was a double carrier of two truncating variants in both POLE and NTHL1. Furthermore, 16 additional patients harbored uncertain significance variants in the remaining tested genes. This report gives information about the contribution of the newly described adenomatous polyposis predisposition genes in a Spanish attenuated polyposis cohort. Our results highly support the convenience of NGS multigene panels for attenuated polyposis genetic screening and reveals POLE frameshift variants as a plausible susceptibility mechanism for AAP.

Indexed as

Gene Regulatory NetworksGerm-Line MutationAdenomatous Polyposis ColiAdultAgedAged, 80 and overCohort StudiesDNA Mutational AnalysisFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingHumansMaleMiddle Aged

Identifiers

PMID31285513
PMCPMC6614360
OpenAlexW2953502518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.